Our biosensor technology is revolutionizing disease diagnosis and monitoring with a simple blood test.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $68.7M
Founded date: 2015
Investors 8
| Date | Name | Website |
| - | Inevitable... | inevitable... |
| - | GreatPoint... | gpv.com/ |
| 17.07.2021 | ARCH Ventu... | archventur... |
| 17.07.2020 | Alumni Ven... | avgfunds.c... |
| - | Section 32 | section32.... |
| - | Catalio Ca... | cataliocap... |
| - | DNS Capita... | dnscap.com |
| 17.07.2020 | New Leaf V... | nlvpartner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 24.07.2020 | Series B | $46.7M | - |
| 17.10.2018 | Series A | $22M | - |
Mentions in press and media 14
| Date | Title | Description |
| 24.07.2020 | Glympse Bio Raises $46.7M in Series B Financing | Glympse Bio, a Cambridge, Mass.-based biotechnology company, closed a $46.7m Series B financing. The round was led by Section 32 and includes new investors Temasek, DNS Capital, New Leaf Venture Partners, Waterman Ventures, and Catalio Capi... |
| 16.07.2020 | Glympse Bio Announces $46.7M Series B | CAMBRIDGE, MA, Glympse Bio has closed an oversubscribed $46.7 million Series B financing. >> Click here for more funding data on Glympse Bio >> To export Glympse Bio funding data to PDF and Excel, click here Glympse Bio (... |
| 15.07.2020 | Glympse Bio Raises $46.7M In Series B | Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, has closed an oversubscribed $46.7 million Series B financing. The proceeds from the financing will support continued developmen... |
| 15.07.2020 | Glympse Bio raises more than $46M in Series B round for biosensor technology | Section 32 led the round, while Temasek, DNS Capital, New Leaf Venture Partners, Waterman Ventures and Catalio Capital Management also signed on as new investors. Existing investors taking part in the round include LS Polaris Innovation Fun... |
| 15.07.2020 | GILEAD SCIENCES, INC. Glympse Bio Raises $46.7 Million in Series B Funding Round | By Colin Kellaher Biotechnology startup Glympse Bio Wednesday said it raised $46.7 million in an oversubscribed Series B financing at an undisclosed valuation. Glympse said Bill Maris' Section 32 venture-capital firm led the round, which al... |
| 17.10.2018 | Eyeing NASH, Glympse Raises $22M to Test Disease Detection Nanotech | - |
| 10.10.2018 | Term Sheet — Wednesday, October 10 | 5 Qs WITH A DEALMAKER Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop “We’ve backed quite a few companies that have started as accidental businesses,” Court told Term Sheet. “The... |
| 09.10.2018 | Glympse Bio Raises $22m Series A Financing | Glympse Bio, a Cambridge, Mass.-based company advancing in vivo sensing technology dedicated to transforming disease monitoring, raised $22m in Series A funding. The round was co-led by LS Polaris Innovation Fund and ARCH Ventures, with par... |
| 09.10.2018 | Glympse Bio raises $22 million in Series A round for disease monitoring tech | The company is developing in vivo sensing technology designed to be transported to the site of disease in patients, examine diseased tissue’s biological activity and then emit a signal that can be detected through urine. The lead indication... |
| 09.10.2018 | Glympse Bio Raises $22M Series A Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Glympse Bio, Inc. announced today that it has raised $22 million in Series A funding. The proceeds of this round will be devoted to conducting clinical trials for its novel platform which uses bioengineere... |
Show more